SpyBiotech Company
SpyBiotech Operators of a biotechnology platform intended to generate next-generation vaccines.The company's biotechnology platform develops bonding vaccines which are made from the proprietary protein superglue which is used to bond antigens to viruses and other particles to make vaccines, enabling medical institutions and research centers with a new and modified technology to develop vaccines which give better results in lesser time.
Last Funding Type:
Series A
Funding Status:
Early Stage Venture
Headquarters:
Oxford, Oxfordshire, United Kingdom
Founded Date:
2017-01-01
Last Funding Date:
2021-02-10
Total Funding:
37490885
Estimated Revenue:
Less than $1M
Investors Number:
5
Industry:
Atrificial Vectors and Immune Cells